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Human Africa trypanosomiasis is a centuries-old disease which has disrupted sub-Saharan Africa in both physical suﬀering and
economic loss. This article presents an update of classic chemotherapeutic agents, in use for >50 years and the recent development
of promising non-toxic combination chemotherapy suitable for use in rural clinics.
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1.Introduction
Human African Trypanosomiasis (HAT) or African try-
panosomiasis has been endemic in sub-Saharan Africa for
thousands of years. Currently approximately 50 million
people are at risk for this disease in an area of 10 million
square kilometers [1] HAT is caused by two hemoﬂagellates
of the Trypanosoma brucei subgroup, T. b. gambiense (West
AfricanorGambian form)andT. b. rhodesiense (EastAfrican
or Rhodesian form). The parasites are transmitted by the
tsetse ﬂy between humans and reservoir domestic and wild
animals. In the early-stage of the disease, the parasite is
found in the bloodstream and lymphatic system. In the later,
central nervous system stage, cerebrospinal ﬂuid, and neural
tissue become infected. Symptoms of early-stage include
fever, chills, headache, and lymphadopathy. In the later
CNS stage, severe headaches, insomnia, progressive mental
deterioration, psychiatric manifestations, and tremors are
common, ﬁnally culminating in coma and death [2]. The
surface of the trypanosome is covered by variant surface
glycoprotein (VSG) which is the main antigenic determinant
to the human immune system [3]. The genome contains
∼1000 genes capable of coding for VSG genes which are
randomly switched on and oﬀ at each generation [4]. This
immune evasion mechanism makes it unlikely that a vaccine
could be developed for HAT.
The attention paid to developing chemotherapy for HAT
has lagged behind that for other tropical diseases [5]. The
agentsinroutineclinicalusehavebeenavailablefor>50years
and are not ideal drugs, some curing only early-stage disease
(pentamidine, berenil or suramin), with the only routinely
available drug for late-stage, CNS disease (Melarsprol, Mel B,
Arsobal) having signiﬁcant toxicity [6]. With the exception
of suramin, resistance to these agents is growing. This is due
in part to development of reduced uptake with melarsoprol
and pentamidine [7].
Diﬂuoromethylornithine (eﬂornithine, DFMO, Ornidy-
lR) is the only new usefuladdition to this list for treatment of
late-stage since the early 1950s [7, 8]. A recent development
has been the success in clinical trial of a DFMO-nifurtimox
combination for CNS disease. This reduces the DFMO
dosage and has no signiﬁcant toxicity [9]. Parafuramidine
maleate (DB289) is being developed as an orally adminis-
tered alternative to intramuscular dosing with pentamidine
in hope that it might facilitate treatment of early-stage, non-
CNS disease [10].
2. Current Chemotherapy
Pentamidine is a water-soluble aromatic diamidine that has
beeninusesincethe1930s.Itiseﬀectiveagainstearly-stageT.
b. gambiense infection, but is less eﬀective against T. b. rhode-
siense infection, and is ineﬀective against late-stage disease
[10, 11]. Dosing for early-stage disease consists of a series
of 7–10 intramuscular injections; however, shorter dose
regimens are being explored [10]. African trypanosomes
have a nucleoside (adenine/adenosine: P2) transporter that
takes up pentamidine, resulting in the concentration of the
agent at levels many times that in plasma [12, 13]. Recent2 Interdisciplinary Perspectives on Infectious Diseases
studies have found two other transporters, besides P2, that
also transport pentamidine and may be responsible for
50% of its uptake [14]. Many studies have focused on the
mechanism of pentamidine action; however, none appears
to conclusively deﬁne the target. It is known to bind to
the minor groove of kinetoplast (mitochondrial) DNA, and
to promote the cleavage of kinetoplast minicircle DNA,
eventually leading to the development of dyskinetoplastic
cells. Despite its eﬀects on kinetoplast DNA, pentamidine
has no eﬀect on nuclear DNA, and dyskinetoplastic forms
can persist in the bloodstream of mammals [10, 11].
Pentamidine was also found to be a reversible inhibitor of
S-adenosylmethionine (AdoMet) decarboxylase, an enzyme
in the polyamine biosynthetic pathway, but this is unlikely
as the primary mechanism of action [10]. Although Ki
values were in the 200-μM range, we now know that this
internal concentration is achievable via uptake through
the P2 nucleoside–pentamidine transporter, and two other
recentlydiscoveredtransportersHAPT1andLAPT1[14,15].
Other targets studied previously in trypanosomes include
the inhibition of glycolysis and lipid metabolism, as well
as eﬀects on amino acid transport and ion exchange. The
fact that pentamidine does not kill trypanosomes outright
and bloodstream forms persist after treatment argue for a
sustained eﬀect more consistent with interference of parasite
nucleic acid metabolism [10, 11].
Diminazene aceturate (Berenil) is an aromatic diamidine
developed by Hoechst as treatment for bovine trypanosomi-
asis; however, its apparent low incidence of adverse reactions
and signiﬁcant therapeutic activity has led some physicians
in endemic countries to use it extensively. It is eﬀective
against early-stage T. b. gambiense and T. b. rhodesiense.
Berenil has also been used in combination with melarsoprol
for the late-stage disease. Mechanistically, like pentamidine,
berenil has also been linked to kinetoplast DNA binding at
the minor groove and cleavage of minicircle DNA. As with
pentamidine, berenil may also interfere with RNA editing
and trans-splicing [11]. Berenil is also a more eﬀective
and noncompetitive inhibitor of AdoMet decarboxylase in
trypanosomes, resulting in the reduction of spermidine
content and elevating putrescine in the parasite. Berenil
uptake, as with pentamidine, occurs via the P2 nucleoside
transporter, which allows signiﬁcant accumulation from the
external environment. The other pentamidine transporters,
HAPT1 and LAPT1 appear to play only a minor role in
bereniluptake[14].Althoughberenilhasbeenusedformany
yearsonthousands of sleeping sickness patients, there is little
published on its toxicity [10, 15]. This may in part be due
to physicians who are unwilling to document human studies
with an agent licensed for veterinary use. However, personal
accounts of those using berenil in humans indicate it is well
tolerated.
Suramin is a sulfonated naphthylamine, which has been
used successfully against early-stage sleeping sickness caused
chieﬂy by T. b. rhodesiense. Suramin does not penetrate the
blood-brain barrier and is not used for CNS-stage disease.
It was ﬁrst used in 1922, developed from the closely related
azo dyes, trypan red, and trypan blue [6, 10]. Suramin
has an extremely long half-life in humans, 44–54 days, the
result of avid binding to serum proteins. Suramin binds to
many plasma proteins including LDL, which trypanosomes
avidly bind and endocytose as a result of speciﬁc membrane
receptors. LDL is a prime source of sterols for bloodstream
trypanosomes [10, 16]. Suramin has been shown to inhibit
all of the glycolytic enzymes in T. b. brucei and also
other enzymes, including those of the pentose phosphate
pathway [10]. This speciﬁcity for trypanosomal enzymes
was attributed to higher (basic) isoelectric points for the
parasite enzyme than the mammalian enzymes, allowing
the negatively charged suramin to bind preferentially to the
parasite enzymes. In practice, because most trypanosome
glycolytic enzymes are contained in a membrane-bound
cytosolic organelle, the glycosome, it is not likely that rapid
massive binding occurs. This would rapidly induce lysis in
bloodstream forms that depend on glycolysis as the sole
energy-generating source. Rather, animals that are heavily
infected with trypanosomes and given suramin show a
slow decrease in parasite numbers, indicating that enzyme
inhibition occurs slowly. Suramin may be aﬀecting newly
synthesized enzyme molecules in the cytosol before they are
imported into the glycosome. Suramin has also been found
to aﬀect thymidine kinase and dihydrofolate reductase. It
is likely that suramin’s action may be attributable to the
inhibition of several of these enzymes [11].
Melarsoprol is an arsenical resulting from the eﬀorts
of Ernst Freidheim in the late 1940s. His initial com-
pound, melarsen oxide, p-(4,6-diamino-s-triazinyl-2-yl)
aminophenylarsenoxide was complexed with dimercapto-
propanol (British Anti-Lewisite) to form a less-toxic com-
plex, merlarsoprol. Until 1990, this was the only agent
available for treatment of late-stage CNS disease both of
East African and West African origin. It is usually given
as two to four series of three daily I.V. injections, or a
single daily injection for 10 days [8]. It is insoluble in
water and must be dissolved in propylene glycol, given
intravenously. For this reason, it is painful to administer
and destroys veins after several applications. Toxicity is an
important concern with melarsoprol. This takes the form of
reactive arsenical-induced encephalopathy in 10% of treated
patients, which is often followed by pulmonary edema and
death in more than half these cases within 48 hour. [8,
17]. Although the mechanism of melarsoprol action has
been extensively studied, it still remains unclear. Parasites
exposed to low (1–10μM) levels rapidly lyse. Because the
bloodstream forms are intensely glycolytic, any interruption
of glycolysis or interference with redox metabolism should
produce this eﬀect. Thus a series of reports has detailed
melarsoprol inhibition of trypanosome pyruvate kinase (Ki,
100μM), phosphofructokinase (Ki, <1μM), and fructose-
2,6-bisphosphatase (Ki, 2μM). It is likely that the rapid
inhibition of fructose 2,6,bis-phosphate production is a key
factor in halting glycolysis through downregulation of pyru-
vate kinase [11]. Other studies indicated that melarsoprol
and melarsen oxide formed adducts with trypanothione
(N1,N8-bisglutathionyl spermidine), a metabolite unique
to trypanosomes and believed to be responsible for the
redox balance of the cell and detoxiﬁcation of peroxides
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inhibits trypanothione reductase, which has been attributed
to the mode of action [19, 20]. However, melarsoprol
and related arsenicals may also bind to other sulfhydryl-
containing agents in the cell, including dihydrolipoate and
the closely adjacent cysteine residues of many proteins.
Similar to pentamidine and diminazene, melarsoprol uptake
into African trypanosomes has been attributed to the P2
purine nucleoside transporter; thus, signiﬁcant levels can
be concentrated in the cell from a low external (plasma)
concentration [12, 13]. Although most laboratory-generated
melarsoprol-resistant strains have lost or modiﬁed the P2
transporter, clinical isolates appear to have retained uptake
capacity [14].
DFMO is the most recently developed agent for late-
stage T. b. gambiense sleeping sickness. DFMO is an enzyme-
activated irreversible inhibitor of ornithine decarboxylase
(ODC), the initial enzyme in the polyamine synthetic path-
way. This agent was initially developed as an antitumor agent
by Merrell-Dow in the late 1970s and underwent extensive
clinical trials before testing against trypanosomes, after
initial testing in mouse model T. b. brucei infections [21].
DFMO was studied extensively in human trials in Africa [22,
23].Thestandardtreatmentregimenresultingfromthetrials
indicatethatDFMOis<95%activewhengivenintravenously
400mg/kg I.V., given every 6 hours. for 14 days. DFMO
cured children, adults, patients with melarsoprol-refractory
strains,andpatientswithlate-stagedisease[17,24]Theshort
plasma half-life of DFMO necessitates constant dosing when
g i v e na sa nI . V .d r i p .T h em o s tf r e q u e n tt o x i cr e a c t i o nw a s
reversible bone marrow suppression, which was alleviated
upon reduction of the doses. The major drawbacks with
respect to DFMO are its cost, the duration of treatment,
and its availability [25]. DFMO rapidly and irreversibly
binds to the catalytic site (cysteine 360) in mouse ODC,
inactivating it. In culture, it blocks division of bloodstream
trypanosomes, but it is not trypanocidal. In laboratory
infections, DFMO cures when administered continuously
in the drinking water as a 2% solution. Within 48 hours
of administration, DFMO reduces putrescine levels to zero,
and reduces spermidine levels by >75% [26]. Trypanothione
levels are also signiﬁcantly reduced [19]. As noted, DFMO
is not trypanocidal and depends on a functional immune
system to rid the host of non-dividing forms [27]. Mor-
phologically, trypanosomes exposed to DFMO have multiple
kinetoplasts and nuclei as well as forms resembling “stumpy”
bloodforms[26].DFMOiscurativeforlaboratoryinfections
of T. b. brucei and T. b. gambiense, but not to all strains
of T. b. rhodesiense [28].The reason for this selectivity is
not completely evident, although it is not due to uptake of
DFMO, because it enters by passive diﬀusion, not transport
[27, 29]. Iten et al 1997 [30] have found that T. b. rhodesiense
isolates have an ODC with a shorter half-life than T. b.
gambiense, which could result in lowered susceptibility to
DFMO. Also levels of AdoMet are highly elevated in DFMO-
treated susceptible T. b. rhodesiense strains, but less so in
refractory isolates [25]. This elevation is the result of the
block in putrescine synthesis and the resulting inability
to make spermidine. The elevated level of AdoMet is the
result of an AdoMet synthase insensitive to its product.
DFMO treatment leads to intracellular concentrations of
>5mM, an increase of >50-fold over untreated parasites
[25]. Trypanosome ODC is missing the C-terminal PEST
sequence in both procyclic and bloodstream trypanosomes,
and this appears to be the major reason for the stability
of the trypanosome enzyme. The remainder of the ODC
molecule has ∼60% sequence identity with the mammalian
enzyme,includingacysteine360residueatthedemonstrated
DFMO-binding site for the mammalian enzyme [31, 32].
Beyond this, trypanosomes lack a polyamine oxidase, which
in mammalian cells converts spermine to the biologically
active spermidine. Trypanosomes are also limited in their
ability to transport putrescine and spermidine [25].
3. DFMO Drug Combinations
Eﬂornithine is the only new agent developed in 58 years
for clinical use of second stage HAT. With relatively minor
and irreversible side eﬀects as compared to melarsoprol, it
is superior in eﬃcacy to melarsoprol [33, 34]. In laboratory
model infections of T. b. brucei,D F M Ow a sc u r a t i v ei n
combination with many new agents as well as clinically-used
trypanocides, including suramin and melarsoprol [35, 36].
In the laboratory, these combinations resulted in signiﬁcant
reduction in DFMO dosage and time of administration [37].
Recent clinical studies have investigated the use of DFMO
in combination with other clinically used trypanocides
[17, 34]. Because of the recent availability of DFMO as a
result of advocacy campaigns by Medicines Sans Frontiers
and other organizations, coupled with ﬁnancial support by
Sanoﬁ-Aventis, DFMO has been increasingly available in
the ﬁeld since 2001 [8]. Initial clinical combination studies
[17] showed that DFMO + nifurtimox was far superior
to DFMO + melarsoprol and melarsoprol + nifurtimox.
The DFMO + nifurtimox regimen (NECT regimen) allowed
r e d u c t i o ni nD F M Or e g i m e nf r o m1 4t o7d a y s( 5 6v e r s u s
28 infusions) with a 94% cure rate. Nifurtimox was given
orally for 10 days. The study has been conﬁrmed in another
clinical study with a DFMO-Nifurtimox cure rate of 100%
[24]. In another related study, total doses of DFMO were
r e d u c e dt o1 4( t w o / d a yf o r7d a y s )a n da9 4 %c u r e
rate resulted with a DFMO-nifurtimox regimen [34]. All
of the DFMO-nifurtimox regimens were associated with
signiﬁcantly reduced adverse side eﬀects as compared to
melarsoprol-based therapy [8]. The biochemical basis for
this therapy most likely lies in the ability of DFMO to
reduce trypanothione levels and resistance to oxidative stress
[19, 20] and the ability of nifurtimox to generate oxidative
stress in trypanosomes [38]. In addition to MSF, Drugs
for Neglected Diseases initiative (DNDi), the Swiss Tropical
Institute, Epicenter, and The World Health Organization,
have collaborated in making these combination clinical trials
possible (HAT-NECT Phase III Study: [9]).
4. Prophylaxis and Prevention
Trypanosomiasis causes complex public health and epizootic
problems in many developing countries in Africa. Control4 Interdisciplinary Perspectives on Infectious Diseases
programs concentrating on the eradication of vectors and
drug treatment of infected people and animals have been in
o p e r a t i o ni ns o m ea r e a sf o rd e c a d e s .C o n s i d e r a b l ep r o g r e s s
has been made in a number of regions, but the lack of agree-
ment on the best approach to solving the problem of African
trypanosomiasis, combined with a paucity of resources,
stands in the way of eﬀective control. Individuals can
reduce their risk of becoming infected with trypanosomes
by avoiding tsetse ﬂy-infested areas, by wearing clothing that
reduces the biting of the ﬂies, and by using insect repellants.
Chemoprophylaxis with suramin or pentamidine can be
eﬀective, but it is not clear which populations should use this
as a preventive measure. No vaccine is available to prevent
the transmission of the parasites.
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